Cemiplimab is a PD-1 monoclonal antibody that blocks PD-1/PD-L1-mediated T-cell suppression. Cemiplimab has been approved for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC).
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.